Streetbeat News

BNTC

Benitec Biopharma Inc.

https://benitec.com

Industry

Biotechnology

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Open

9.38

Mkt cap

229M

Volume

39K

High

10.11

P/E Ratio

-3.36

52-wk high

12.89

Low

9.10

Div yield

N/A

52-wk low

2.69

Benitec Biopharma released its Q1 2025 financial results and provided an operational update, highlighting positive interim clinical study data for its BB-301 treatment.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

Benitec Biopharma has filed with the SEC for a mixed shelf offering of up to $125 million. This move allows the company to raise capital through various financial instruments, which could be used for corporate purposes such as research and development, or to strengthen its balance sheet.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 9:09 pm

Oppenheimer has initiated coverage on Benitec Biopharma with an Outperform rating and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 9:12 am

Top Wall Street analysts have updated their price targets and ratings for several companies, including JPMorgan Chase, Nurix Therapeutics, V.F. Corporation, Affirm Holdings, Snap Inc., Wells Fargo, Benitec Biopharma, Boot Barn Holdings, Fastenal Company, and ArcBest Corporation. These changes reflect varying outlooks on the companies' future performance.

Portfolio Pulse from Avi Kapoor

October 14, 2024 | 2:29 pm

JMP Securities has maintained a Market Outperform rating on Benitec Biopharma and raised its price target from $16 to $18.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 12:55 pm

Benitec Biopharma reported positive interim results from its Phase 1b/2a study of BB-301, showing significant improvements in swallowing for two subjects. A conference call is scheduled for October 14 to discuss these findings.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 7:29 am

Several healthcare stocks experienced significant price movements during Tuesday's intraday session. Notable gainers included Nuwellis, Sagimet Biosciences, and Opthea, while Gritstone Bio and Applied DNA Sciences were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 4:31 pm

JMP Securities has reiterated its Market Outperform rating for Benitec Biopharma (NASDAQ:BNTC) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:35 pm

Benitec Biopharma reported a fiscal year 2024 EPS of $(5.51) and announced that its cash runway is extended through 2025.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 8:40 pm

Benitec Biopharma is set to present a late-breaking oral abstract on its BB-301 Phase 1b/2a clinical study at the 29th Annual World Muscle Society Congress in October 2024. This presentation could provide significant insights into the progress and potential of BB-301.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.